First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors

Investigational New Drugs

Volumn 33, Issue 2, 2015, Pages 440-449

  Lorusso, Patricia M ^a,d   Goncalves, Priscila H ^a   Casetta, Lindsay ^a   Carter, Judith A ^b   Litwiler, Kevin ^c   Roseberry, Dale ^c   Rush, Selena ^c   Schreiber, Jennifer ^c   Simmons, Heidi M ^c   Ptaszynski, Mieke ^c   Sausville, Edward A ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c ARRAY BIOPHARMA INC   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ARRY 520; Filanesib; First in human; KSP inhibitor; Solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; FILANESIB; KIF11 PROTEIN, HUMAN; KINESIN; MEMBRANE PROTEIN; PMEPA1 PROTEIN, HUMAN; THIADIAZOLE DERIVATIVE;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HALF LIFE TIME; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PHASE 1 CLINICAL TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; KINESIN; MALE; MAXIMUM TOLERATED DOSE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASMS; THIADIAZOLES;

EID: 84939959421     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0211-0     Document Type: Article

References (25)

1. Schmidt M, Bastians H (2007) Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 10:162-181. doi: 10.1016/j.drup.2007.06.003
2. Morris PG, Fornier MN (2008) Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 14:7167-7172. doi: 10.1158/1078-0432.CCR-08-0169
3. Janssen A, Medema RH (2011) Mitosis as an anti-cancer target. Oncogene 30:2799-2809. doi: 10.1038/onc.2011.30
4. Sarli V, Giannes A (2008) Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res 14:7583-7587. doi: 10.1158/1078-0432.CCR-08-0120
5. Miglarese MR, Carlson RO (2006) Development of new cancer therapeutic agents targeting mitosis. Expert Opin Investig Drugs 15:1411-1425. doi: 10.1517/13543784.15.11.1411
6. Drummond DR (2011) Regulation of microtubule dynamics by kinesins. Semin Cell Dev Biol 22:927-934. doi: 10.1016/j.semcdb.2011.09.021
7. Vale RD, Milligan RA (2000) The way things move: looking under the hood of molecular motor proteins. Science 288:88-95. doi: 10.1126/science.288.5463.88
8. Blangy A, Lane HA, d'Hérin P, Harper M, Kress M, Nigg EA (1995) Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83:1159-1169. doi: 10.1016/0092-8674(95)90142-6
9. Stern BM, Murray AW (2001) Lack of tension at kinetochores activates the spindle checkpoint in budding yeast. Curr Biol 11:1462-1467. doi: 10.1016/S0960-9822(01)00451-1
10. Vijapurkar U, Wang W, Herbst R (2007) Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer Res 67:237-245. doi: 10.1158/0008-5472.CAN-06-2406
11. Wojcik EJ, Buckley RS, Richard J, Liu L, Huckaba TM, Kim S (2013) Kinesin-5: cross-bridging mechanism to targeted clinical therapy. Gene 531:133-149. doi: 10.1016/j.gene.2013.08.004
12. Sakowicz R, Finer JT, Beraud C, Crompton A, Lewis E, Fritsch A et al (2004) Antitumor activity of a kinesin inhibitor. Cancer Res 64:3276-280. doi: 10.1158/0008-5472.CAN-03-3839
13. Huszar D, Theoclitou ME, Skolnik J, Herbst R (2009) Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 28:197-208. doi: 10.1007/s10555-009-9185-8
14. El-Nassan HB (2013) Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. Eur J Med Chem 62:614-631. doi: 10.1016/j.ejmech.2013.01.031
15. Woessner R, Tunquist B, Lemieux C, Chlipala E, Jackinsky S, Dewolf W Jr et al (2009) ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. Anticancer Res 29:4373-4380
16. Woessner RD, Corrette C, Allen S, Hans J, Zhao Q, Aicher T et al (2007) ARRY-520, a KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumors. Proc Am Assoc Cancer Res 48:1433
17. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL et al (2002) Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 100:194-199. doi: 10.1182/blood.V100.1.194
18. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ (2003) Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426:671-676. doi: 10.1038/nature02067
19. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K et al (2005) Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307:1101-1104. doi: 10.1126/science.1106114
20. Zhang B, Gojo I, Fenton RG (2002) Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99:1885-1893. doi: 10.1182/blood.V99.6.1885
21. Tunquist BJ, Woessner RD, Walker DH (2010) Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol Cancer Ther 9:2046-2056. doi: 10.1158/1535-7163.MCT-10-0033
22. Lonial S, Shah JJ, Zonder J, Bensinger WI, Cohen AD, Kaufman JL et al (2013) Prolonged survival and improved response rates with ARRY-520 in relapsed/refractory multiple myeloma (RRMM) patients with low α-1 acid glycoprotein (AAG) levels: results from a Phase 2 study. Blood 122:285
23. Shah JJ, Feng L, Thomas SK, Weber DM, Wang M, Hilder B et al (2013) Phase 1 Study of the novel kinesin spindle protein inhibitor ARRY-520∈+∈carfilzomib (Car) in patients with relapsed and/or refractory multiple myeloma (RRMM). Blood 122:1982
24. Chari A, Htut M, Zonder J, Fay JW, Jakubowiak AJ, Harrison B et al (2013) A Phase 1 study of ARRY-520 with bortezomib (BTZ) and dexamethasone (dex) in relapsed or refractory multiple myeloma (RRMM). Blood 122:1938
25. Chari A, Htut M, Zonder J, Fay JW, Jakubowiak AJ, Harrison B et al. (2014) Phase 1 study of filanesib (ARRY-520) with bortezomib (BTZ) and dexamethasone (dex) in relapsed or refractory multiple myeloma (RRMM). Presented at the 19th Congress of European Hematology Association (EHA), 06 June 2014, Milan, Italy. P370 (abstract)